Ropes & Gray Logo
Page Translations

Tara M. Fisher

Partner
Areas of Practice
  • *
Jump to:

Accomplished deal lawyer Tara Fisher guides clients through their most strategically important transactions. For more than 15 years, public and private companies, boards of directors, and investment banks have relied on Tara to navigate billion-dollar mergers and acquisitions, sophisticated capital market transactions, and critical corporate governance matters. Clients praise her ability to act as an extension of their business and legal teams.

Tara advises on both domestic and cross-border mergers and acquisitions, joint ventures, divestitures, spin-offs, and strategic investments. She also has experience counseling on shareholder activism and takeover defense matters.

Clients across industries—ranging from life sciences, medical devices and healthcare to retail and industrials—count on Tara for pragmatic and strategic advice. She deftly navigates complex structures, focuses on clients’ business needs, and combines deep market knowledge, sound technical skills and innovative thinking. In recent years, she has also helped clients spot opportunity in turbulent markets.

Above all, Tara’s practice is defined by the longstanding relationships she has developed with clients. Senior management and boards of directors depend on Tara’s proactive advice and appreciate her ability to bring together the right team to get a deal across the finish line.

Experience

Mergers & Acquisitions

  • Represented Immunogen in its $10.1 billion sale to AbbVie.
  • Represented CIRCOR in its $1.6 billion sale to KKR.
  • Represented Paratek Pharmaceuticals in its sale to Gurnet Point Capital and Novo Holdings.
  • Represented TransMedics Group Inc. in its acquisition from Bridge to Life Ltd. of assets and intellectual property related to the Ex-Vivo Organ Support System (EVOSS) and LifeCradle Heart Preservation Transport System technologies.
  • Represented Medtronic in its $1.1 billion acquisition of Intersect ENT.
  • Represented CIRCOR in its defense of an unsolicited bid and in a proxy contest with an activist investor.
  • Represented Novavax, Inc., a clinical-stage vaccine company, in its acquisition of a Czech Republic company Praha Vaccines a.s., a part of the Cyrus Poonawalla Group, and in a cross-border tender offer for the outstanding shares of Isconova, a Sweden-based public vaccine adjuvant company.
  • Represented Pfizer in connection with its $14 billion acquisition of Medivation, a commercial-stage oncology company.
  • Represented Medtronic in connection with its $1.3 billion acquisition of HeartWare International, a heart pump manufacturer.
  • Represented Shire plc in its $32 billion combination with Baxalta Incorporated, a business spun out of Baxter International, for a combination of cash and stock
  • Represented Shire plc its acquisition of Dyax Corp. for $5.9 billion in cash plus contingent value rights.
  • Represented The TJX Companies, Inc., the leading off-price retailer of apparel and home fashions in the U.S. and worldwide, in its acquisition of Sierra Trading Post, Inc., an off-price Internet retailer.
  • Represented The Strategic Alternatives Special Committee for Market Basket, a chain of discount supermarkets in the northeast, in its $1.5 billion sale.

Capital Markets

  • Represented the lead underwriters in the $219 million IPO of Sionna Therapeutics common stock.
  • Represented the lead underwriters in the $308 million IPO and $488 million follow-on offering of Loar Holdings Inc., a manufacturer and supplier of aerospace and defense components.
  • Represented the lead underwriters in the $500 million and $600 million follow-ons offering of Madrigal Pharmaceuticals common stock.
  • Represented the lead underwriters in the $125 million follow-on offering of 2seventybio common stock.
  • Represented the lead underwriters in the $121 million follow-on offering of bluebird bio common stock.
  • Represented the lead underwriters in the $91 million IPO of Vigil Neuroscience.
  • Represented the lead underwriters in the $181 million IPO of Entrada Therapeutics.
  • Represented the lead underwriters in the $6.7 billion secondary offering of Regeneron common stock.
  • Represented the lead underwriters in the $550 million IPO and concurrent $250 million tangible equity unit offering for Change Healthcare, an independent health care technology platform
  • Represented the lead underwriters in the $1.7 billion Elanco Animal Health IPO and the dealer managers in the $8.6 billion exchange of Elanco stock for Lilly stock.
  • Represented the lead underwriters in the $725 million common stock offering and concurrent $550 million tangible equity unit offering for Elanco Animal Health to finance the Bayer Animal Health business acquisition.
  • Represented TransMedics Group, Inc., a medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients, in its $105 million IPO and $70 million follow-on offering.
  • Represented PQ Group Holdings Inc., a provider of performance chemicals, catalysts, and specialty glass materials and a portfolio company of CCMP, in its $500 million IPO.
  • Represented The TJX Companies, Inc., the leading off-price retailer of apparel and home fashions in the U.S. and worldwide, in its $500 million, $750 million, $1 billion and $4 billion registered note offerings.

Areas of Practice